UpToDate
UpToDate خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده: 4

Terms, definitions, and characterizing risk factors for indefinite anticoagulation

Terms, definitions, and characterizing risk factors for indefinite anticoagulation
Term Definition and examples
No identifiable risk factor (unprovoked) VTE where no identifiable provoking event or risk factor is evident
Identifiable risk factor (provoked) VTE caused by a known event or risk factor (eg, surgery, hospital admission, estrogen)
Transient risk factor Risk factors for VTE that are reversible
  • Major risk factors (ie, transient factors that favor limited-duration anticoagulation):
    • Major surgery >30 minutes, hospitalization or confined to bed with "bathroom privileges" for ≥3 days due to acute illness, trauma with fractures, estrogen therapy, pregnancy or puerperium
  • Minor risk factors (ie, transient factors that favor continuing anticoagulation):
    • Minor surgery <30 minutes, hospitalization <3 days, reduced mobility at home ≥3 days due to acute illness, lower extremity injury without fracture with reduced mobility ≥3 days, long-haul flight
Persistent risk factor Risk factors that persist over a prolonged period of time
  • Examples include irreversible conditions such as active malignancy, obesity, active inflammatory bowel disease, active autoimmune disease, continued hormonal therapy, nephrotic syndrome, recurrent long-haul flights
Proximal DVT of lower extremity VTE in the popliteal, femoral, or iliac veins
Distal DVT of lower extremity VTE without a proximal component and confined to the calf veins (peroneal, posterior, anterior tibial, and muscular veins). The popliteal vein is not involved.
Pulmonary embolism Thrombus in the main, lobar, segmental, or subsegmental branches of the pulmonary artery
Phases of anticoagulation therapy
  • Initiation phase (initial therapy) – Administered immediately following a diagnosis of VTE.
  • Treatment phase (also called "maintenance phase" or "long-term") – Administered for a finite period beyond initiation, usually 3 to 6 months and occasionally up to 12 months.
  • Extended phase (indefinite) – Administered beyond the finite period, sometimes indefinitely.
DOACs Includes direct factor Xa and thrombin inhibitors. Also known as newer/novel oral anticoagulants (NOAs), non-vitamin K antagonist oral anticoagulants (NOACs), and target-specific oral anticoagulants (TOACs, TSOACs).
DOACs: direct oral anticoagulants; DVT: deep venous thrombosis; VTE: venous thromboembolism.
Graphic 131266 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟